RSV Burden of disease

RSV Is a Common Respiratory Virus With Symptoms Varying by Age-Group

Abbreviation

COPD, chronic obstructive pulmonary disease; LRTIs, lower respiratory tract infections; mos, months; yrs, years.

References

Adapted from: Openshaw PJM, et al. Annu Rev Immunol. 2017;35:501-532.
Carvajal JJ, et al. Front Immunol. 2019;10:2152.
Falsey AR,et al. N Engl J Med. 2005;352(17):1749-1759.

RSV Causes Substantial Disease Burden for Newborns and Infants Globally

Based on 2019 global data.

Reference

Li Y, et al. Lancet. 2022 May 19:S0140-6736(22)00478-0. doi: 10.1016/S0140-6736(22)00478-0.

RSV is a Leading Cause of LRTIs Among Infants Worldwide^1,2

Estimated Percentage of acute LRTI attributable to RSV infection

LRTI, lower respiratory tract infection. Data are derived from different studies and over different years. aOnly includes hospitalizations due to bronchiolitis; bRSV was a cause of 28% of all hospitalization cases in infants in France. References

LRTI, lower respiratory tract infection. Data are derived from different studies and over different years.

^aOnly includes hospitalizations due to bronchiolitis; bRSV was a cause of 28% of all hospitalization cases in infants in France.

References

Nair H, et al. Lancet. 2010;375(9725):1545-55.
Shi T, et al. Lancet. 2017;390(10098):946-958.
Rha B, et al. Pediatrics. 2020;146(1):e20193611.
Reeves RM, et al. Influenza Other Respir Viruses. 2017;11(2):122-129.
El-Hajje MJ, et al. Eur J Pediatr. 2008;167(4):435-436.
Weigl J, et al. Eur J Clin Microbiol Infect Dis. 2001;20(7):452-9.
Sanchez-Luna M, et al. Curr Med Res Opin. 2016;32(4):693-698.
Cangiano G, et al. Pediatr Pulmonol. 2016;51(12):1330-1335.
Zhang Y, et al. J Global Health. 2015;5(2):020417.
Inagaki A, et al. Jpn J Infect Dis. 2021;74(1):23-28.
Ahmed, A., et al. (2018). "An overview of respiratory syncytial virus infections in Saudi Arabia." The Journal of Infection in Developing Countries 12(11): 929-936
Alkharsah, K. R. (2022). "The Scope of Respiratory Syncytial Virus Infection in a Tertiary Hospital in the Eastern Province of Saudi Arabia and the Change in Seasonal Pattern during and after the COVID-19 Pandemic." Medicina 58(11): 1623.

Prevalence in RSV hospitalized with bronchiolitis during seasonal epidemics

^aCoronavirus type OC43, 229E, NL63, and HKU1. Age range of children not specified.

References

Meissner HC. N Engl J Med. 2016;374(1):62-72.
Al Aql, F., et al. (2016). "Guidelines for palivizumab prophylaxis in infants and young children at increased risk for respiratory syncytial virus infection in Saudi Arabia.
" International Journal of Pediatrics and Adolescent Medicine 3(1): 38-42.
Elham E, B. and E. Malak M (2013).
"Viral agents causing acute lower respiratory tract infections in hospitalized children at a tertiary care center in Saudi Arabia."

RSV Average Hospitalization days

5.9 days in hospital

6.5 days in hospital

total of 754 beds (502 inpatient beds, 56 emergency beds, 77 ICU beds, 32 psychiatry beds, and 87 special auxiliary beds).

^AComorbidities assessed: congenital cardiopathies, 2.3%; congenital defects with cardiac affectation, 0.7%; prematurity, 0.3%; bronchopulmonary dysplasia, 1%.

References

Gil-Prieto R, et al. Medicine (Baltimore). 2015;94(21):e831.,
Alkharsah, K. R. (2022).
"The Scope of Respiratory Syncytial Virus Infection in a Tertiary Hospital in the Eastern Province of Saudi Arabia and the Change in Seasonal Pattern during and after the COVID-19 Pandemic." Medicina 58(11): 1623.

RSV Causes Substantial Hospitalization Among All Infants and Young Children In Spain

Epidemiologic survey in Spain estimating the burden of RSV in all children <5 years of age during a 15-year period (1997–2011)¹

326,175
hospital discharges

Due to bronchiolitis in children <5 years of age

5.9 days
in hospital

on average in children ≤2 years of age

4,136/100,000 incidence of hospitalization during 1st yearof life

highest incidence among all age ranges

446
deaths

355 (80%)<12 months of age 335 (75%) without comorbidities^*

96.8 % of children were otherwise healthy

Only 3.2% of children <5 years of age presented with ≥1 comorbidity*

^AComorbidities assessed: congenital cardiopathies, 2.3%; congenital defects with cardiac affectation, 0.7%; prematurity, 0.3%; bronchopulmonary dysplasia, 1%.

Reference